君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

交易中 03-19 15:32:51

21.780

-0.360

-1.63%

最高22.700	最低21.540	成交量416.72万
今开21.800	昨收22.140	日振幅5.24%
总市值223.68亿	流通市值56.63亿	总股本10.27亿
成交额9,192万	换手率1.60%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":21.78,"timestamp":1773905563805,"preClose":22.14,"halted":0,"volume":4167200,"delay":0,"changeRate":-0.01626016260162599,"floatShares":260000000,"shares":1027000000,"eps":-0.87,"marketStatus":"交易中","change":-0.36,"latestTime":"03-19 15:32:51","open":21.8,"high":22.7,"low":21.54,"amount":91921318,"amplitude":0.052394,"askPrice":21.78,"askSize":1800,"bidPrice":21.76,"bidSize":28200,"shortable":3,"etf":0,"ttmEps":-0.907,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1773907800000},"marketStatusCode":2,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":22.14,"openAndCloseTimeList":[[1773883800000,1773892800000],[1773896400000,1773907200000]],"volumeRatio":1.331612,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":33.32,"timestamp":1773903600000,"preClose":33.36,"halted":0,"volume":12953500,"delay":0,"premium":"-42.40"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"1151941272","title":"异动解读 | 研发管线进展积极叠加控股股东增持，君实生物盘中大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151941272","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151941272?lang=zh_cn&edition=full","pubTime":"2026-03-17 10:19","pubTimestamp":1773713947,"startTime":"0","endTime":"0","summary":"君实生物今日盘中股价大幅拉升，涨幅一度达到5.04%，引起了市场的广泛关注。消息面上，公司近期召开了业绩说明会，向市场详细披露了其丰富的创新药研发管线进展。这些进展凸显了公司在肿瘤治疗领域的深厚布局和长期增长潜力。与此同时，公司控股股东、实际控制人之一兼董事长持续增持公司股份，截至最新公告日已累计增持金额超1200万元，且增持计划尚未完成，这进一步向市场传递了内部人士对公司未来发展前景的坚定信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01877"],"gpt_icon":0},{"id":"2620416592","title":"君实生物：3月13日召开业绩说明会，长江证券、兴业证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2620416592","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620416592?lang=zh_cn&edition=full","pubTime":"2026-03-17 09:16","pubTimestamp":1773710179,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年3月16日君实生物发布公告称公司于2026年3月13日召开业绩说明会，长江证券、兴业证券、中邮证券、中金公司、中泰证券、浙商证券、投资者、广发证券、国联民生证券、国泰海通证券、国金证券、华安证券、开源证券、太平洋证券、瑞银证券参与。JS005注射部位反应发生率仅1%,明显低于同类药物。答：特瑞普利单抗已于中美欧等全球40多个国家和地区获得批准上市。该股最近90天内共有1家机构给出评级，增持评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700008475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000783","BK0183","BK1161","BK0188","BK1583","BK0012","601377","688180","BK0201","BK1515","01877","BK0028","BK0276"],"gpt_icon":0},{"id":"2619246863","title":"君实生物(01877)获董事长熊俊累计增持36.54万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619246863","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619246863?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:57","pubTimestamp":1773662249,"startTime":"0","endTime":"0","summary":"截至本公告披露日，熊俊先生通过上海证券交易所系统以集中竞价方式累计增持公司A股股份36.54万股，约占公司总股本的0.04%，累计成交总额为人民币1220.66万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增持计划，在增持计划实施期间内择机增持公司股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","159982","BK1161","BK1583","399300","01877","688180","BK1515"],"gpt_icon":0},{"id":"2619431806","title":"君实生物：2025年营收增长28.23%至24.98亿元，商业化药品销售收入与上年同期相比有所增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2619431806","media":"财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619431806?lang=zh_cn&edition=full","pubTime":"2026-03-16 13:07","pubTimestamp":1773637620,"startTime":"0","endTime":"0","summary":"近日，君实生物发布公告称，2025年君实生物实现营业收入24.98亿元，同比增长28.23%；归属于母公司所有者的净利润亏损8.75亿元，上年同期净利润亏损12.81亿元。公司2025年度不进行利润分配，也不进行资本公积转增股本。营业收入同比增长，主要系商业化药品的销售收入与上年同期相比有所增长。归属于上市公司股东的净利润较上年同期亏损减少主要系商业化药品的销售收入与上年同期相比有所增长。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-16/doc-inhreeew9895503.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-16/doc-inhreeew9895503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01877","688180"],"gpt_icon":0},{"id":"2619712589","title":"君实生物(688180)2月28日股东户数3.8万户，较上期增加8.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619712589","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619712589?lang=zh_cn&edition=full","pubTime":"2026-03-14 17:02","pubTimestamp":1773478968,"startTime":"0","endTime":"0","summary":"证券之星消息，近日君实生物披露，截至2026年2月28日公司股东户数为3.8万户，较12月31日增加2953.0户，增幅为8.44%。户均持股数量由上期的2.19万股减少至2.02万股，户均持股市值为68.64万元。在生物制品行业个股中，君实生物股东户数高于行业平均水平，截至2月28日，生物制品行业平均股东户数为3.45万户。从股价来看，2025年12月31日至2026年2月28日，君实生物区间跌幅为0.47%，在此期间股东户数增加2953.0户，增幅为8.44%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031400013280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1583","688180","BK1515","01877"],"gpt_icon":0},{"id":"2619314290","title":"君实生物2025年报：减亏超三成，肿瘤药战场迎双抗分水岭","url":"https://stock-news.laohu8.com/highlight/detail?id=2619314290","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619314290?lang=zh_cn&edition=full","pubTime":"2026-03-14 11:01","pubTimestamp":1773457288,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛在创新药行业依旧处于资本寒冬的“降本增效”主旋律中，君实生物交出了2025年成绩单。3月13日晚间，君实生物（1877.HK，688180.SH）发布的2025年年度报告显示，公司在报告期内实现营业收入24.98亿元，同比增长28.23%；归母净亏损收窄至8.75亿元，同比大幅减亏31.68%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603143672192095.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603143672192095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1161","BK1583","688180","BK1515","01877"],"gpt_icon":0},{"id":"2619114878","title":"图解君实生物年报：第四季度单季净利润同比增长21.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114878","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619114878?lang=zh_cn&edition=full","pubTime":"2026-03-14 01:13","pubTimestamp":1773421994,"startTime":"0","endTime":"0","summary":"证券之星消息，君实生物2025年年报显示，当年度公司主营收入24.98亿元，同比上升28.23%；归母净利润-8.75亿元，同比上升31.68%；扣非净利润-9.9亿元，同比上升23.28%；其中2025年第四季度，公司单季度主营收入6.93亿元，同比上升2.28%；单季度归母净利润-2.79亿元，同比上升21.09%；单季度扣非净利润-3.2亿元，同比上升8.63%；负债率51.09%，投资收益-1.06亿元，财务费用6527.3万元，毛利率81.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031400000956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","688180"],"gpt_icon":0},{"id":"2619194120","title":"君实生物(01877)：战略委员会调整为战略与ESG委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194120","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619194120?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:58","pubTimestamp":1773403132,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)发布公告，为进一步提升公司环境、社会及公司治理(ESG)管理水平，增强公司可持续发展能力，根据有关法律规定及公司章程，结合公司实际情况，董事会已决议将原董事会下设战略委员会调整为战略与ESG委员会，自2026年3月13日起生效，并将原《战略委员会工作细则》调整为《战略与ESG委员会工作细则》，在原有职权基础上增加ESG管理等职责。战略与ESG委员会主要负责对公司长期发展战略和重大投资决策、可持续发展和ESG进行研究并向董事会提出建议。本次调整仅就该委员会名称和职责进行调整，其人员组成、任期规定等不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","688180","BK1161","BK1583","159717","ESG","BK0239","BK1515"],"gpt_icon":0},{"id":"2619196762","title":"君实生物2025年亏损减少至8.75亿元 营收增长28.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619196762","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619196762?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:57","pubTimestamp":1773399455,"startTime":"0","endTime":"0","summary":"3月13日，君实生物(688180)公布2025年年报，公司营业收入为25.0亿元，同比上升28.2%；归母净利润自去年同期亏损12.8亿元变为亏损8.75亿元，亏损额有所减少；扣非归母净利润自去年同期亏损12.9亿元变为亏损9.9亿元，亏损额有所减少；经营现金流净额为-5.2亿元，同比增长63.8%；EPS(全面摊薄)为-0.8524元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603133671689256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688180","01877"],"gpt_icon":0},{"id":"2619714196","title":"君实生物：证券事务代表王雨舟辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2619714196","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619714196?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:49","pubTimestamp":1773398958,"startTime":"0","endTime":"0","summary":"南财智讯3月13日电，君实生物公告，公司董事会于近日收到证券事务代表王雨舟女士递交的书面辞职报告。王雨舟女士因个人原因申请辞去公司证券事务代表职务，辞职后不再担任公司任何职务。王雨舟女士的辞职报告自送达公司董事会之日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603133671684673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1583","161027","01877","BK1515","688180","BK1161"],"gpt_icon":0},{"id":"2619196742","title":"君实生物：拟使用不超过15.00亿元部分闲置募集资金暂时补充流动资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2619196742","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619196742?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:49","pubTimestamp":1773398958,"startTime":"0","endTime":"0","summary":"君实生物：拟使用不超过15.00亿元部分闲置募集资金暂时补充流动资金","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603133671684361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688180","BK1515","BK0239","01877","BK1583","BK1161"],"gpt_icon":0},{"id":"2618130583","title":"君实生物（688180）披露归还暂时用于补充流动资金的闲置募集资金公告，3月12日股价下跌0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618130583?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:17","pubTimestamp":1773325035,"startTime":"0","endTime":"0","summary":"截至2026年3月12日收盘，君实生物报收于31.14元，较前一交易日下跌0.57%，最新总市值为319.71亿元。近日，君实生物发布《关于归还暂时用于补充流动资金的闲置募集资金的公告》。公司实际使用110,634.16万元闲置募集资金用于补充流动资金，并已按期于2026年3月13日前将该笔资金全部归还至募集资金专用账户，同时通知了保荐机构和保荐代表人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200038735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK1583","BK1515","688180","BK1161","BK0239"],"gpt_icon":0},{"id":"1106021052","title":"君实生物获批使用不超过20亿元闲置资金临时补充流动性","url":"https://stock-news.laohu8.com/highlight/detail?id=1106021052","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106021052?lang=zh_cn&edition=full","pubTime":"2026-03-12 19:29","pubTimestamp":1773314945,"startTime":"0","endTime":"0","summary":"君实生物（股票代码：01877/688180）宣布，公司已通过决议，批准使用额度不超过20亿元人民币（含）的闲置募集资金，用于临时补充流动资金。此举旨在提高资金使用效率，降低财务成本，为公司的日常经营和业务发展提供更灵活的财务支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1161","BK1583","01877","688180","BK1515"],"gpt_icon":0},{"id":"2618209915","title":"增持384万元，仅完成最低计划7.7%！期限只剩1个月，君实生物董事长不宜“雷声大雨点小”","url":"https://stock-news.laohu8.com/highlight/detail?id=2618209915","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618209915?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:51","pubTimestamp":1773211910,"startTime":"0","endTime":"0","summary":"2026年3月10日盘后，君实生物（SH688180）发布公告，披露了公司控股股东、实际控制人之一兼董事长熊俊增持计划的进展。根据公告，熊俊自2025年4月启动的亿元级增持计划已临近到期（剩余约1个月），但截至目前仅累计增持A股10万股，成交金额约383.84万元，距离5000万元的最低目标尚有超过4500万元的缺口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603113668743989.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113668743989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1583","BK1161","BK1515","01877","688180"],"gpt_icon":0},{"id":"2618937911","title":"君实生物(01877)获董事长熊俊累计增持10万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937911","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618937911?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:48","pubTimestamp":1773143300,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)发布公告，有关公司控股股东、实际控制人之一兼董事长熊俊先生拟自2025年4月12日起12个月内，通过上海证券交易所交易系统与香港联合交易所有限公司允许的方式(包括但不限于集中竞价和大宗交易等方式)增持公司A股股份及H股股份，合计增持金额不低于人民币1亿元，其中A股增持金额不低于人民币5000万元。截至本公告披露日，熊俊先生通过上海证券交易所系统以集中竞价方式累计增持公司A股股份10万股，约占公司总股本的0.01%，累计成交总额为人民币383.84万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增持计划，在增持计划实施期间内择机增持公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688180","BK1161","BK1583","159982","BK0239","01877","BK1515","399300"],"gpt_icon":0},{"id":"1126313246","title":"君实生物董事长拟增持公司A+H股 金额不低于1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126313246","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126313246?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:46","pubTimestamp":1773143178,"startTime":"0","endTime":"0","summary":"君实生物（股票代码：01877.HK，688180.SH）宣布，公司董事长计划通过二级市场增持公司A股及H股股份，拟增持总金额不低于人民币1亿元。此次增持行动彰显了公司管理层对企业未来发展的坚定信心以及对长期价值的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1583","BK1161","BK1515","01877","688180"],"gpt_icon":0},{"id":"2618601211","title":"港股异动 | 君实生物(01877)早盘涨超7% 特瑞普利单抗注射液(皮下注射)上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2618601211","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618601211?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:45","pubTimestamp":1773107132,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物早盘涨超7%，截至发稿，涨6.54%，报20.2港元，成交额2149.32万港元。消息面上，据君实生物消息，君实生物自主研发的特瑞普利单抗注射液皮下注射剂型用于肿瘤治疗的12项适应症上市申请，已获得国家药品监督管理局受理。该产品为首款进入上市申报阶段的国产抗PD-1单抗皮下制剂，有望显著提升肿瘤免疫治疗的便捷性。皮下注射剂型相较于目前主流的静脉输注，将能缩短给药时间，优化患者治疗体验与医疗资源配置。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","01877","VXUS","BK1583","BK1515","688180","BK0239","BK1161"],"gpt_icon":0},{"id":"2618629489","title":"君实生物：特瑞普利单抗注射液（皮下注射）上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2618629489","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618629489?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:10","pubTimestamp":1773061813,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月9日，君实生物(688180.SH)公告称，公司收到国家药品监督管理局核准签发的《受理通知书》，公司产品特瑞普利单抗注射液（皮下注射）（代号：JS001sc）用于肿瘤治疗的12项适应症的上市申请获得受理。JS001sc是公司在已上市产品特瑞普利单抗注射液（代号：JS001）的基础上开发的皮下注射制剂，为首款进入上市申报阶段的国产抗PD-1单抗皮下注射制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603093666328598.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666328598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","BK1583","BK1515","BK1161","BK0239","688180"],"gpt_icon":0},{"id":"2617663351","title":"每周股票复盘：君实生物（688180）将发布2025年全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663351?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:58","pubTimestamp":1772909890,"startTime":"0","endTime":"0","summary":"公司公告汇总君实生物H股公告上海君实生物医药科技股份有限公司董事会谨定于2026年3月13日举行会议，以考虑及通过本集团截至2025年12月31日止年度的全年业绩，以及考虑派发末期股息（如有）和其他事项。君实生物H股公告上海君实生物医药科技股份有限公司截至2026年2月28日的证券变动月报表显示，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1583","01877","688180","BK1515"],"gpt_icon":0},{"id":"2617517006","title":"君实生物（688180）披露截至2026年2月28日证券变动月报表，3月5日股价上涨0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517006","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617517006?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:24","pubTimestamp":1772702658,"startTime":"0","endTime":"0","summary":"公司于近日披露《截至2026年2月28日的证券变动月报表》。公告显示，截至2026年2月28日，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于香港联交所上市，A股于上交所科创板上市。股份期权计划方面，H股及A股股票期权激励计划已于2025年9月29日获批准采纳，本月无新增行权或股份变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260305/32047274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["161027","BK1515","BK1161","BK0239","BK1583","688180","01877"],"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":0.1081},{"period":"1month","weight":0.0563},{"period":"3month","weight":-0.0151},{"period":"6month","weight":-0.3103},{"period":"1year","weight":0.4566},{"period":"ytd","weight":0.0375}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0255},{"period":"3month","weight":0.0207},{"period":"6month","weight":-0.0196},{"period":"1year","weight":0.0519},{"period":"ytd","weight":0.0154}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.062525},{"month":3,"riseRate":0.75,"avgChangeRate":0.053118},{"month":4,"riseRate":0.857143,"avgChangeRate":0.101581},{"month":5,"riseRate":0.428571,"avgChangeRate":0.004505},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.018268},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.014588},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.026161},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}